Breast cancer is the most common malignancy in terms of incidence and is the leading cause of cancer deaths among women worldwide. In the Philippines, 33,079 new cases of breast cancer were documented in 2020 comprising 17.5% of all new cancer diagnoses. With a rate of 27 deaths per 100,000 people, the Philippines is the frontrunner in Asia for breast cancer mortality. HER2/neu-positive breast cancer, a more aggressive subtype associated with poorer survival outcomes, is present in about 23.5%. Fortunately, the emergence of HER2-targeted therapies has considerably improved disease-free survival and overall survival. This article reviews the most recent data in the HER2+ early breast cancer space.
Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
